Who is sponsoring NCT03437811?

NCT03437811 is sponsored by Mack Biotech, Corp..

What drugs are being tested in NCT03437811?

Interventions in NCT03437811: Electro Flo Percussor, Model 5000.

What condition does NCT03437811 study?

NCT03437811 studies Cystic Fibrosis, Pulmonary.

Is NCT03437811 still recruiting?

NCT03437811 is currently completed. Last updated 10 April 2020.

Last reviewed 2020-04-10 · How we verify

NCT03437811

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Airway Clearance System (K031876) Phase IV Device Efficacy

Completed Last updated 10 April 2020

What this trial tests

trial testing Electro Flo Percussor, Model 5000 in Cystic Fibrosis, Pulmonary in 16 participants. Completed in 1 November 2019.

Timeline

28 February 2018

Primary endpoint
1 November 2019

1 November 2019

Quick facts

Lead sponsor	Mack Biotech, Corp.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	16
Start date	28 February 2018
Primary completion	1 November 2019
Estimated completion	1 November 2019
Sites	1 location across United States

Drugs / interventions tested

Electro Flo Percussor, Model 5000

Conditions studied

Cystic Fibrosis, Pulmonary — all drugs for Cystic Fibrosis, Pulmonary →

Sponsor

Mack Biotech, Corp.

Who can join

Adults 18 to 55, any sex, with Cystic Fibrosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase IV interventional study of adults (18 to 55) having a diagnosis of cystic fibrosis (mild, moderate or severe). The study is completely voluntary and is designed to measure participants use and the effectiveness of the device within the 510K indication of: airway clearance therapy when external manipulation of the thorax. The trial period shall be 21 days and include use of a FDA cleared pulse oximetry monitor (K131111), manual spirometer as well as completion of semi-weekly participant survey.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis, Pulmonary

Currently open trials in the same condition.

NCT06084468 — Cardiac Structure and Function in Patients with Cystic Fibrosis · active not recruiting
NCT05604495 — Screening for Cystic Fibrosis and Cystic Fibrosis Related Disorders in Chinese Adults With Bronchiectasis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03437811 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mack Biotech, Corp.
Last refreshed: 10 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03437811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing